Indian pharma resilient to US tariffs; Eyes US pricing reform gains: Ind-Ra

The US generic market is crucial for Indian pharma, contributing about 35% to its total revenue, around US$ 10.7 billion

Akums Drugs and Pharmaceuticals signs framework agreement with Govt. of Zambia

This project shall be implemented through incorporation of a new joint venture company in Zambia

UFlex posts Q1 FY26 PAT at Rs. 58 Cr

The company’s virgin PET chips plant in Egypt, commissioned in Q4 FY25, achieved 74.8 per cent capacity utilization in its first full quarter. In India, the Panipat facility operated at 96.6 per cent utilization

Marksans Pharma reports Q1 FY26 gross profit 8.9% higher at Rs. 358.2 Cr

EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent

Wockhardt reports Q1 FY26 loss at Rs. 108 Cr

Consolidated revenue from operations in the quarter was marginally down at Rs 738 crore a

Akums reports Q1 FY26 PAT at Rs. 65 Cr

During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals

Zydus completes acquisition of 85.6% stake in Amplitude Surgical

Fortis and Agilus expand rapid genomic testing capabilities

The Genexus platform enables Next-Generation Sequencing with significantly faster turnaround times

Aurobindo to acquire Lannett Company for Rs. 2,185 Cr

The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities

Akums launches high-strength Paracetamol oral suspension 500mg/5ml

Akums bridges the long-standing gap between paediatric syrups and conventional tablet formats